An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 31 Oct 2019 Expanded results from the trial presented in the Aldeyra media release.
- 31 Oct 2019 Primary endpoint (Ocular itching evaluated by the Subject.) has been met, according to the Aldeyra media release.
- 30 Oct 2019 According to an Aldeyra Therapeutics media release, the company will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from this trial.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History